ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12, 2024 07:30 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
March 05, 2024 17:10 ET
|
Crossbow Therapeutics
Crossbow Therapeutics today announced the nomination of its first development candidate, CBX-250, a T-cell engager for the treatment of myeloid leukemia.
Monthly information on share capital and company voting rights
March 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, March 04, 2024 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Getting Healthcare Innovations to Patients Faster with the Proven Kymanox Hyper-Virtual Model™
February 27, 2024 10:00 ET
|
Kymanox
Morrisville, North Carolina, USA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kymanox Corporation (“Kymanox”), a professional services company exclusively serving life sciences, announced today the launch of...
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
February 15, 2024 18:35 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
Monthly information on share capital and company voting rights
February 02, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
February 01, 2024 07:00 ET
|
Societal CDMO, Inc.
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing...
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science
January 31, 2024 07:00 ET
|
Orange Grove Bio
CINCINNATI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orange Grove Bio, a drug investment and development firm, today announced that it has established a new strategic collaboration with Bina, the...
First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...